Prosecution Insights
Last updated: May 29, 2026
Application No. 18/419,894

ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Non-Final OA §DOUBLEPATENT
Filed
Jan 23, 2024
Priority
Jul 10, 2017 — provisional 62/530,778 +6 more
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Celgene Corporation
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
877 granted / 1134 resolved
+17.3% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
24 currently pending
Career history
1144
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
19.1%
-20.9% vs TC avg
§102
32.1%
-7.9% vs TC avg
§112
22.8%
-17.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1134 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Claims 43-55 are pending in the instant application. 2. Claim Rejections - Obvious Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, In re Thorington, 418 F.2d 528, 168 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130 (b). Effective January 1,1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 43-55 are rejected under the judicially created doctrine obviousness-type double patenting as being unpatentable over the claims 1-20 of US 11,185,543. Although the conflicting claims are not identical, they are not patentably distinct from each other because the current invention embraces the invention claimed in the above patent. Determination of the scope and content of the prior art (MPEP §2141.01) ‘543 claims analogues compound and method of using the compound in claims 1-20 as the instant claims 43-55. Ascertainment of the difference between the prior art and the claims (MPEP §2141.02) The difference between the instant claims 43-55 and the claims 1-20 of ‘543 patent is the claims are not word for word identical but the scope of the two sets of claims overlaps significantly with each other. Finding of prima facia obviousness-rational and motivation (MPEP §2142.2143) All the elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. 3. Claims 43-55 are rejected under the judicially created doctrine obviousness-type double patenting as being unpatentable over the claims 11-26 of US 10,357,489. Although the conflicting claims are not identical, they are not patentably distinct from each other because the current invention embraces the invention claimed in the above patent. Determination of the scope and content of the prior art (MPEP §2141.01) ‘489 claims analogues compound and method of using the compound in claims 11-26 as the instant claims 43-55. Ascertainment of the difference between the prior art and the claims (MPEP §2141.02) The difference between the instant claims 43-55 and the claims 11-26 of ‘489 patent is the claims are not word for word identical but the scope of the two sets of claims overlaps significantly with each other. Finding of prima facia obviousness-rational and motivation (MPEP §2142.2143) All the elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ 03/08/2026
Read full office action

Prosecution Timeline

Jan 23, 2024
Application Filed
Mar 11, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637462
INTEGRIN INHIBITOR AND USES THEREOF
2y 2m to grant Granted May 26, 2026
Patent 12630558
PYRIDINE DERIVATIVES AS MODULATORS OF SORTILIN ACTIVITY
2y 10m to grant Granted May 19, 2026
Patent 12624030
4-AMINO-3-(4-PHENOXYPHENYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF
2y 10m to grant Granted May 12, 2026
Patent 12624031
INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS
3y 0m to grant Granted May 12, 2026
Patent 12617789
SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE
2y 7m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
74%
With Interview (-2.9%)
1y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1134 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month